Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.

[1]  M. Suarez‐Almazor,et al.  Process of Care and Outcomes in Patients with Peripheral Arterial Disease , 2007, Journal of General Internal Medicine.

[2]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[3]  P. Greenland,et al.  Atherosclerotic risk factor reduction in peripheral arterial disease , 2002, Journal of General Internal Medicine.

[4]  J. Blacher,et al.  Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. , 2006, Journal of vascular surgery.

[5]  Deepak L. Bhatt,et al.  The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. , 2006, American heart journal.

[6]  Jeroen J. Bax,et al.  Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. , 2006, Journal of the American College of Cardiology.

[7]  Rodney A. White,et al.  ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography , 2006, Circulation.

[8]  P. Greenland,et al.  Atherosclerotic Risk Factors Are Less Intensively Treated in Patients with Peripheral Arterial Disease Than in Patients with Coronary Artery Disease , 1997, Journal of General Internal Medicine.

[9]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[10]  P. Greenland,et al.  Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. , 2003, Archives of internal medicine.

[11]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[12]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[13]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[14]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[15]  V. Fuster,et al.  AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.

[16]  M. Criqui,et al.  Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care , 2001 .

[17]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[18]  J. Eikelboom,et al.  Low rates of preventive practices in patients with peripheral vascular disease. , 1999, The Canadian journal of cardiology.

[19]  A. Clark,et al.  Cholesterol in peripheral vascular disease--a suitable case for treatment? , 1999, QJM : monthly journal of the Association of Physicians.

[20]  D L Sackett,et al.  Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. , 1996, Circulation.

[21]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[22]  R. Langer,et al.  Mortality over a period of 10 years in patients with peripheral arterial disease. , 1992, The New England journal of medicine.

[23]  L. Kuller,et al.  The ratio of ankle and arm arterial pressure as an independent predictor of mortality. , 1991, Atherosclerosis.

[24]  D. Sumner,et al.  Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. , 1989, Journal of vascular surgery.